ATE254463T1 - Verwendung von valaciclovir zur herstellung eines arzneimittels zur behandlung von genitalherpes durch einmal tägliche verabreichung - Google Patents

Verwendung von valaciclovir zur herstellung eines arzneimittels zur behandlung von genitalherpes durch einmal tägliche verabreichung

Info

Publication number
ATE254463T1
ATE254463T1 AT97901052T AT97901052T ATE254463T1 AT E254463 T1 ATE254463 T1 AT E254463T1 AT 97901052 T AT97901052 T AT 97901052T AT 97901052 T AT97901052 T AT 97901052T AT E254463 T1 ATE254463 T1 AT E254463T1
Authority
AT
Austria
Prior art keywords
valaciclovir
genital herpes
once daily
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
AT97901052T
Other languages
English (en)
Inventor
John Delehanty
Margaret L Smiley
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24399659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE254463(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE254463T1 publication Critical patent/ATE254463T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicinal Preparation (AREA)
AT97901052T 1996-01-19 1997-01-17 Verwendung von valaciclovir zur herstellung eines arzneimittels zur behandlung von genitalherpes durch einmal tägliche verabreichung ATE254463T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59944896A 1996-01-19 1996-01-19
PCT/EP1997/000192 WO1997025989A1 (en) 1996-01-19 1997-01-17 Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application

Publications (1)

Publication Number Publication Date
ATE254463T1 true ATE254463T1 (de) 2003-12-15

Family

ID=24399659

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97901052T ATE254463T1 (de) 1996-01-19 1997-01-17 Verwendung von valaciclovir zur herstellung eines arzneimittels zur behandlung von genitalherpes durch einmal tägliche verabreichung

Country Status (12)

Country Link
EP (1) EP0874631B1 (de)
JP (1) JP4097698B2 (de)
AT (1) ATE254463T1 (de)
AU (1) AU722304B2 (de)
CA (1) CA2243237C (de)
CY (1) CY2512B1 (de)
DE (1) DE69726255T2 (de)
DK (1) DK0874631T3 (de)
ES (1) ES2210490T3 (de)
PT (1) PT874631E (de)
WO (1) WO1997025989A1 (de)
ZA (1) ZA97400B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
ITMI20010009A1 (it) * 2001-01-03 2002-07-03 Menarini Ricerche Spa Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera
WO2003022209A2 (en) * 2001-09-07 2003-03-20 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
US6849737B2 (en) * 2001-11-14 2005-02-01 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
WO2004000265A2 (en) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
AU2003232719A1 (en) * 2003-05-30 2005-01-21 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
CN1331471C (zh) * 2003-09-22 2007-08-15 陈云芳 盐酸万乃洛韦软胶囊组合物
WO2007090595A1 (en) * 2006-02-06 2007-08-16 Fidia Pharmaceutici S.P.A. Solid formulations of valacyclovir hydrochloride
GB0605344D0 (en) * 2006-03-17 2006-04-26 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
JP4669804B2 (ja) * 2006-03-28 2011-04-13 株式会社オーディオテクニカ コンデンサマイクロホン
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
CN104188928B (zh) * 2014-09-17 2017-07-28 山东新时代药业有限公司 一种盐酸伐昔洛韦片剂及其制备方法
WO2020049536A1 (en) * 2018-09-07 2020-03-12 Jubilant Generics Limited Pharmaceutical compositions of valacyclovir or its pharmaceutically acceptable salts thereof
CN109651371B (zh) * 2018-12-31 2021-02-23 辰欣药业股份有限公司 一种盐酸伐昔洛韦的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
GB9320316D0 (en) * 1993-10-01 1993-11-17 Smithkline Beecham Plc Pharmaceuticals
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
JP4097698B2 (ja) 2008-06-11
AU1443497A (en) 1997-08-11
ZA97400B (en) 1997-11-13
ES2210490T3 (es) 2004-07-01
CA2243237C (en) 2008-09-02
AU722304B2 (en) 2000-07-27
JP2000503310A (ja) 2000-03-21
EP0874631A1 (de) 1998-11-04
EP0874631B1 (de) 2003-11-19
CA2243237A1 (en) 1997-07-24
DE69726255T2 (de) 2004-08-26
DE69726255D1 (de) 2003-12-24
CY2512B1 (en) 2005-12-23
PT874631E (pt) 2004-04-30
WO1997025989A1 (en) 1997-07-24
DK0874631T3 (da) 2004-03-22

Similar Documents

Publication Publication Date Title
CY2512B1 (en) Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
JPH02184628A (ja) 関節炎疾患および炎症疾患に対する治療方法
UA40589C2 (uk) Спосіб лікування людини, що страждає від вірусної інфекції, фармацевтична композиція, комбінація речовин для отримання ліків та фармацевтична комбінація
JP2004531468A5 (de)
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
JPH02502278A (ja) とくに後天性免疫不全状態の処置のための、免疫調整及び抗ウイルス効果を有する医薬の調製におけるモルヒネ拮抗剤の使用
NO306894B1 (no) Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet
AU2004233587A1 (en) Use of a topical medicament comprising Riluzole
US4438138A (en) Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
CA2795038C (en) Opioid receptor antagonist (naltrexone) for use in treating herpes zoster disease
KR970061244A (ko) 치매 치료용 약학 조성물
JPH08283148A (ja) うつ性症状改善剤
JPH06500537A (ja) アテローム硬化症の治療のためのアリールヒドロキシ尿素化合物の使用
NO974486L (no) Lavdoserte "Ridogrel"-formuleringer samt anvendelse derav ved behandling av tarmbetennelse
CN112972462B (zh) 帕比司他在制备预防、缓解和/或治疗多发性硬化症药物中的应用
JPH0415766B2 (de)
CN112972448B (zh) 贝利司他在制备预防、缓解和/或治疗多发性硬化症药物中的应用
JP2000186040A (ja) 抗ｈｉｖ感染症剤
JPH04342528A (ja) アルコール代謝およびアセトアルデヒド代謝促進剤
JP2729340B2 (ja) 痴呆症治療剤
WO1992015315A1 (en) Method for the treatment of herpes
AR020167A1 (es) Metodo para la prevencion del inicio del asma
JPH0826980A (ja) 抗ウイルス剤

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0874631

Country of ref document: EP

REN Ceased due to non-payment of the annual fee